Healthcare Stocks in Focus: GlucoTrack, Helius Medical Tech, and More
ByAinvest
Monday, Jul 21, 2025 11:38 am ET1min read
EVO--
GlucoTrack shares rose by 104.1% to $11.9, with a market cap of $3.3 million [2]. The company's recent positive clinical trial results and the repurchase of Series A Warrants may have contributed to the surge in retail chatter and investor interest [1].
Helius Medical Tech (HSDT) saw an increase of 86.62% to $16.61, with a market value of $6.2 million [2]. The company's recent developments in medical technology could be driving the optimism among investors.
On the other hand, Evotec (EVO) stock fell by 12.7% to $3.72, with a market cap of $1.5 billion [2]. The decline was likely due to the company's revised revenue forecast for fiscal year 2025, citing weaker-than-expected performance in its Shared R&D base business [3].
Lisata Therapeutics (LSTA) shares decreased by 11.07% to $2.25, with a market cap of $21.7 million [2]. The company's recent financial performance and market conditions may have influenced the drop in stock price.
These movements reflect the dynamic nature of the healthcare sector, where positive clinical trial results and strategic initiatives can drive significant price increases, while financial setbacks and regulatory concerns can lead to substantial declines.
References:
[1] https://stocktwits.com/news-articles/markets/equity/gluco-track-sarepta-tnf-pharma-dominate-weekly-retail-health-care-buzz/ch8qwPPR5AB
[2] https://www.benzinga.com/insights/movers/25/07/46516082/12-health-care-stocks-moving-in-mondays-pre-market-session
[3] https://www.investing.com/news/stock-market-news/evotec-stock-tumbles-after-slashing-2025-revenue-guidance-93CH-4143966
GCTK--
HSDT--
LSTA--
SRPT--
In Monday's pre-market session, several health care stocks moved significantly. Gainers include GlucoTrack GCTK, which rose 104.1% to $11.9, and Helius Medical Tech HSDT, which increased by 86.62% to $16.61. Losers include Evotec EVO, which fell 12.7% to $3.72, and Lisata Therapeutics LSTA, which decreased by 11.07% to $2.25.
In Monday's pre-market session, several healthcare stocks exhibited significant price movements. GlucoTrack (GCTK) and Helius Medical Tech (HSDT) were notable gainers, while Evotec (EVO) and Lisata Therapeutics (LSTA) experienced declines.GlucoTrack shares rose by 104.1% to $11.9, with a market cap of $3.3 million [2]. The company's recent positive clinical trial results and the repurchase of Series A Warrants may have contributed to the surge in retail chatter and investor interest [1].
Helius Medical Tech (HSDT) saw an increase of 86.62% to $16.61, with a market value of $6.2 million [2]. The company's recent developments in medical technology could be driving the optimism among investors.
On the other hand, Evotec (EVO) stock fell by 12.7% to $3.72, with a market cap of $1.5 billion [2]. The decline was likely due to the company's revised revenue forecast for fiscal year 2025, citing weaker-than-expected performance in its Shared R&D base business [3].
Lisata Therapeutics (LSTA) shares decreased by 11.07% to $2.25, with a market cap of $21.7 million [2]. The company's recent financial performance and market conditions may have influenced the drop in stock price.
These movements reflect the dynamic nature of the healthcare sector, where positive clinical trial results and strategic initiatives can drive significant price increases, while financial setbacks and regulatory concerns can lead to substantial declines.
References:
[1] https://stocktwits.com/news-articles/markets/equity/gluco-track-sarepta-tnf-pharma-dominate-weekly-retail-health-care-buzz/ch8qwPPR5AB
[2] https://www.benzinga.com/insights/movers/25/07/46516082/12-health-care-stocks-moving-in-mondays-pre-market-session
[3] https://www.investing.com/news/stock-market-news/evotec-stock-tumbles-after-slashing-2025-revenue-guidance-93CH-4143966

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet